# RAPT Therapeutics, Inc. — tender_offer/third_party [announced]
Source: SEC API (secapi.ai) · situation sit_14be3a7455c98f80649b · retrieved 2026-08-11T16:13:20.796Z

## Overview
RAPT Therapeutics, Inc. is a pharmaceutical company developing therapeutic treatments.

Redrose Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline LLC (which is an indirect wholly-owned subsidiary of GSK plc), launched a tender offer to purchase all issued and outstanding shares of RAPT Therapeutics, Inc. for $58.00 per share in cash, net to stockholders and less applicable tax withholding. The Offer to Purchase was dated February 2, 2026, and the tender offer was described in a Schedule TO filed jointly by GSK plc, GlaxoSmithKline LLC, and Redrose Acquisition Co. on February 2, 2026. This Amendment No. 1 to the Schedule 14D-9 was filed on February 24, 2026, to supplement certain disclosures and address stockholder litigation and demand letters challenging disclosures in the original Schedule 14D-9.

## Terms
- Counterparty: Redrose Acquisition Co. (subsidiary of GlaxoSmithKline LLC / GSK plc) · Consideration: cash · Price/share: $58

## Key dates
- Announced 2026-02-24

## Timeline
- 2026-02-24 · SC 14D9/A (0001193125-26-065056): SC 14D9/A - RAPT Therapeutics, Inc. — *RAPT Therapeutics, Inc. is a pharmaceutical company developing therapeutic treatments.* Redrose Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline LLC (which is an indirect wholly-owned subsidiary of GSK plc), launched a tender offer to purchase all issued and outstanding shares of RAPT Therapeutics, Inc. for $58.00 per share in cash, net to stockholders and less applicable tax withholding. The Offer to Purchase was dated February 2, 2026, and the tender offer was described in a Schedule TO filed jointly by GSK plc, GlaxoSmithKline LLC, and Redrose Acquisition Co. on February 2, 2026. This Amendment No. 1 to the Schedule 14D-9 was filed on February 24, 2026, to supplement certain disclosures and address stockholder litigation and demand letters challenging disclosures in the original Schedule 14D-9.
  https://www.sec.gov/Archives/edgar/data/1673772/0001193125-26-065056.txt

## Citations
- 0001193125-26-065056 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526065056